Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

T. M. Cox, J. M F G Aerts, N. Belmatoug, M. D. Cappellini, S. Dahl, J. Goldblatt, G. A. Grabowski, C. E M Hollak, P. Hwu, M. Maas, A. M. Martins, P. K. Mistry, G. M. Pastores, A. Tylki-Szymanska, J. Yee, N. Weinreb

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semi-quantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.

Original languageEnglish
Pages (from-to)319-336
Number of pages18
JournalJournal of Inherited Metabolic Disease
Volume31
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Gaucher Disease
Bone Diseases
Diphosphonates
Splenectomy
Biomarkers
Pregnancy
Therapeutics
Disease Management
Consensus
Bone Marrow
Guidelines
Enzymes
Research

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Endocrinology

Cite this

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. / Cox, T. M.; Aerts, J. M F G; Belmatoug, N.; Cappellini, M. D.; Dahl, S.; Goldblatt, J.; Grabowski, G. A.; Hollak, C. E M; Hwu, P.; Maas, M.; Martins, A. M.; Mistry, P. K.; Pastores, G. M.; Tylki-Szymanska, A.; Yee, J.; Weinreb, N.

In: Journal of Inherited Metabolic Disease, Vol. 31, No. 3, 06.2008, p. 319-336.

Research output: Contribution to journalArticle

Cox, TM, Aerts, JMFG, Belmatoug, N, Cappellini, MD, Dahl, S, Goldblatt, J, Grabowski, GA, Hollak, CEM, Hwu, P, Maas, M, Martins, AM, Mistry, PK, Pastores, GM, Tylki-Szymanska, A, Yee, J & Weinreb, N 2008, 'Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring', Journal of Inherited Metabolic Disease, vol. 31, no. 3, pp. 319-336. https://doi.org/10.1007/s10545-008-0779-z
Cox, T. M. ; Aerts, J. M F G ; Belmatoug, N. ; Cappellini, M. D. ; Dahl, S. ; Goldblatt, J. ; Grabowski, G. A. ; Hollak, C. E M ; Hwu, P. ; Maas, M. ; Martins, A. M. ; Mistry, P. K. ; Pastores, G. M. ; Tylki-Szymanska, A. ; Yee, J. ; Weinreb, N. / Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. In: Journal of Inherited Metabolic Disease. 2008 ; Vol. 31, No. 3. pp. 319-336.
@article{defced546bf349e49cd9200155b539ed,
title = "Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring",
abstract = "Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semi-quantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.",
author = "Cox, {T. M.} and Aerts, {J. M F G} and N. Belmatoug and Cappellini, {M. D.} and S. Dahl and J. Goldblatt and Grabowski, {G. A.} and Hollak, {C. E M} and P. Hwu and M. Maas and Martins, {A. M.} and Mistry, {P. K.} and Pastores, {G. M.} and A. Tylki-Szymanska and J. Yee and N. Weinreb",
year = "2008",
month = "6",
doi = "10.1007/s10545-008-0779-z",
language = "English",
volume = "31",
pages = "319--336",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

AU - Cox, T. M.

AU - Aerts, J. M F G

AU - Belmatoug, N.

AU - Cappellini, M. D.

AU - Dahl, S.

AU - Goldblatt, J.

AU - Grabowski, G. A.

AU - Hollak, C. E M

AU - Hwu, P.

AU - Maas, M.

AU - Martins, A. M.

AU - Mistry, P. K.

AU - Pastores, G. M.

AU - Tylki-Szymanska, A.

AU - Yee, J.

AU - Weinreb, N.

PY - 2008/6

Y1 - 2008/6

N2 - Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semi-quantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.

AB - Enzyme replacement was introduced as treatment for non-neuronopathic Gaucher disease more than 15 years ago. To ensure the best use of this costly ultra-orphan agent, a systematic disease management approach has been proposed by an international panel; this includes the development, by consensus, of achievable treatment goals. Here we critically review these goals and monitoring guidelines and incorporate emerging experience of the disease in the therapeutic era, as well as contemporary clinical research. This review makes recommendations related specifically to the management of pregnancy; the appropriate use of splenectomy and bisphosphonate treatment; the relevance of biochemical markers to disease monitoring; and the use of semi-quantitative methods for assessing bone marrow infiltration. In addition, we identify key areas for development, including the requirement for a validated index of disease severity; the need to correlate widely used biomarkers with long-term disease outcomes, and the desirability of establishing agreed standards for monitoring of bone disease particularly in infants and children with Gaucher disease.

UR - http://www.scopus.com/inward/record.url?scp=45849102732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849102732&partnerID=8YFLogxK

U2 - 10.1007/s10545-008-0779-z

DO - 10.1007/s10545-008-0779-z

M3 - Article

C2 - 18509745

AN - SCOPUS:45849102732

VL - 31

SP - 319

EP - 336

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -